Associate Professor Thomas Scriba has co-authored a research paper titled "Individual-level factors associated with variation in mycobacterial-specific immune response: Gender and previous BCG vaccination status."
Associate Professor Mark Hatherill, has co-authored a paper titled: "First-in-human trial of a live-attenuated Mycobacterium tuberculosis vaccine" appearing in the December issue of the Lancet Respiratory Medicine.
On Thursday 17 December SATVI Director Mark Hatherill, spoke to Azania Mosaka from Radio 702 and Cape Talk about the work that SATVI is doing to develop a biomarker test to predict whether a person is at risk of developing full-blown TB. Listen to the interview online.
Researchers from SATVI have participated in a study resulting in the publication of a paper titled "A side-by-side comparison of T cell reactivity to fifty-nine Mycobacterium tuberculosis antigens in diverse populations from five continents".